Automated Preparation of Oligonucleotide-Loaded Lipid Nanoparticles Using Andrew+™

February 29, 2024
8:00 a.m. PST / 11:00 a.m. EST / 16:00 GMT / 17:00 CET - Duration: 60 Minutes


The progress in RNA-based therapies has seen significant advancements, including the approval of pioneering treatments like patisiran in 2018 and the recent development of COVID-19 vaccines using Lipid nanoparticle (LNP) formulations. Researchers have optimized the effectiveness of these therapies by leveraging electrostatic complexation of anionic RNA, utilizing a composition of cationic and ionizable lipids, combined with other lipids. High-throughput screening using robotic automation in a 96-well plate format has emerged as an efficient method, demonstrating results comparable to the current state-of-the-art methods. 

To automate the LNP formulation for screening purposes, a protocol was established using the Andrew+ liquid handling platform. The method was developed to overcome challenges such as rapid evaporation of ethanolic lipid solutions. The automated method maintained consistent particle size and high mRNA encapsulation efficiency. The transfection efficiency into HepG2 cells was comparable to both manual pipetting and microfluidics based LNP preparation methods. Thus, the automated method using Andrew+ has shown promise in streamlining LNP formulation and advancing the development of mRNA-based therapies, offering high precision and repeatability for the high-throughput screening of various LNPs. 

Key Learning Objectives:
  • Preparation of mRNA loaded LNPs 
  • Comparison of manual pipetting, automated pipetting using Andrew+ and microfluidic methods 
  • LNP characterization and high-throughput in vitro screening 
Who Should Attend:
  • Researchers, industry laboratory heads and technicians in the field of LNP formulation or pipetting automation 
  • Students new to the field of LNP formulation 

Brought to you by:
Waters Corporation Logo


Dr. Ryan Karongo
Scientific Labhead, Drug Targeting and Vectors Team,
Bayer AG
Dr. Michael Karimov
Research Scientist, Drug Targeting and Vectors Department,
Bayer AG
Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group


*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

© 2024 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy